Related Experiment Video

Updated: Mar 19, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Progress and Prospects in Pediatric Leukemia

P Pallavi Madhusoodhan1, William L Carroll1, Teena Bhatla1

  • 1Division of Pediatric Hematology Oncology, Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY.

Current Problems in Pediatric and Adolescent Health Care
|June 11, 2016
PubMed

Insights

Childhood leukemia, a common pediatric cancer, has seen survival improvements, especially for acute lymphoblastic leukemia (ALL). However, challenges remain for myeloid leukemia and specific ALL subgroups, driving precision medicine advancements.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Biology

Background:

  • Pediatric leukemia is the most common childhood cancer, accounting for up to 30% of all pediatric malignancies.
  • Significant survival improvements for acute lymphoblastic leukemia (ALL) have been achieved over the last 40 years, with current survival rates nearing 90% in recent studies.
  • Progress in treating myeloid leukemia and specific pediatric leukemia subgroups, including infant ALL, adolescent/young adult ALL, and relapsed ALL, has been slower.

Purpose of the Study:

  • To review the current understanding of the biology of various childhood leukemias.
  • To highlight recent research advances in the field of pediatric leukemia.
  • To discuss future challenges and directions in pediatric leukemia research and treatment.

Main Methods:

  • Review of current scientific literature on pediatric leukemia.
  • Analysis of survival data and treatment outcomes for different leukemia types and subgroups.
  • Discussion of emerging molecular classifications and their impact on treatment strategies.

Main Results:

  • Survival rates for pediatric acute lymphoblastic leukemia (ALL) have dramatically improved, exceeding 90% in recent studies.
  • Slower progress has been observed in improving outcomes for pediatric myeloid leukemia and specific ALL subgroups (infant, adolescent/young adult, relapsed).
  • Recognition of distinct molecular subgroups is paving the way for precision medicine approaches in pediatric leukemia.

Conclusions:

  • While survival for pediatric ALL has significantly improved, further research is crucial for myeloid leukemias and challenging ALL subgroups.
  • Precision medicine, driven by molecular subtyping, represents a promising future direction for optimizing pediatric leukemia treatment.
  • Continued investigation into leukemia biology and collaborative research efforts are essential to overcome future challenges in the field.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

816
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360